DTx Pharma hired Peter Condon as its chief business officer, the privately held biotech company announced Tuesday. Condon will be responsible for shaping DTx Pharma’s business development strategy as the biotech advances its pipeline of RNA therapeutics for rare diseases.
Condon brings more than 20 years of experience in business development, commercial planning and operations. He founded an independent consultancy last year. Prior to that, Condon held positions as VP and head of business development at Gossamer Bio, along with senior roles in business development and commercial planning at Calico Life Sciences, Alexion Pharmaceuticals and Genentech.
